Department of Pathology and Laboratory Medicine, The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mod Pathol. 2014 Nov;27(11):1489-98. doi: 10.1038/modpathol.2014.54. Epub 2014 Apr 18.
The role of sentinel lymph node biopsy in microinvasive breast carcinoma is unclear. We examined the incidence of lymph node metastasis in patients with microinvasive carcinoma who underwent surgery at our institution. Retrospective review of our pathology database was performed (1994-2012). Of 7000 patients surgically treated for invasive breast carcinoma, 99 (1%) were classified as microinvasive carcinoma. Axillary staging was performed in 81 patients (64, sentinel lymph node biopsy; 17, axillary lymph node excision). Seven cases (9%) showed isolated tumor/epithelial cells in sentinel nodes. Three of these seven cases showed reactive changes in lymph nodes, papillary lesions in the breast with or without displaced epithelial cells within biopsy site tract, or immunohistochemical (estrogen receptor, progesterone receptor, and HER2) discordance between the primary tumor in the breast and epithelial cells in the lymph node, consistent with iatrogenically transported epithelial cells rather than true metastasis. The remaining four cases included two cases, each with a single cytokeratin-positive cell in the subcapsular sinus detected by immunohistochemistry only, and two cases with isolated tumor cells singly and in small clusters (<20 cells per cross-section) by hematoxylin and eosin and immunohistochemistry. The exact nature of cytokeratin-positive cells in the former two cases could not be determined and might still have represented iatrogenically displaced cells. In the final analysis, only two cases (3%) had isolated tumor cells. Three of these four cases had additional axillary lymph nodes excised, which were all negative for tumor cells. At a median follow-up of 37 months (range 6-199 months), none of these patients had axillary recurrences. Our results show very low incidence of sentinel lymph node involvement (3%), only as isolated tumor cells, in microinvasive carcinoma patients. None of our cases showed micrometastases or macrometastasis. We recommend reassessment of the routine practice of sentinel lymph node biopsy in patients with microinvasive carcinoma.
前哨淋巴结活检在微浸润性乳腺癌中的作用尚不清楚。我们检查了在我们机构接受手术治疗的微浸润性乳腺癌患者的淋巴结转移发生率。对我们的病理学数据库进行了回顾性分析(1994-2012 年)。在 7000 例接受浸润性乳腺癌手术治疗的患者中,有 99 例(1%)被归类为微浸润性癌。81 例患者进行了腋窝分期(64 例行前哨淋巴结活检;17 例行腋窝淋巴结切除)。7 例(9%)在前哨淋巴结中发现孤立肿瘤/上皮细胞。这 7 例中的 3 例显示淋巴结反应性改变,乳房内有乳头状病变,或活检部位内有上皮细胞移位,或原发性乳腺癌与淋巴结上皮细胞之间的免疫组化(雌激素受体、孕激素受体和 HER2)不一致,符合医源性转移的上皮细胞,而非真正的转移。其余 4 例包括 2 例,免疫组化仅检测到单个位于包膜下窦的细胞角蛋白阳性细胞,2 例孤立的肿瘤细胞,单个或小簇(每个横截面上<20 个细胞),苏木精和伊红及免疫组化染色。前两例中细胞角蛋白阳性细胞的确切性质无法确定,仍可能代表医源性移位细胞。最后分析,仅有 2 例(3%)存在孤立肿瘤细胞。这 4 例中有 3 例进一步行腋窝淋巴结切除,均未见肿瘤细胞。这些患者的中位随访时间为 37 个月(范围 6-199 个月),均无腋窝复发。我们的结果显示微浸润性癌患者前哨淋巴结受累(3%)的发生率非常低,仅为孤立的肿瘤细胞。我们的病例均未发现微转移或大转移。我们建议重新评估微浸润性癌患者常规行前哨淋巴结活检的做法。